Erasca (ERAS) Projected to Release Quarterly Earnings on Tuesday

Erasca (NASDAQ:ERAS) will likely be posting its Q2 2026 results after the market closes on Tuesday, August 11th. Analysts expect Erasca to post earnings of ($0.1114) per share for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 4:00 PM ET.

Erasca (NASDAQ:ERAS) last announced its earnings results on Monday, May 11th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.48). On average, analysts expect Erasca to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Erasca Stock Performance

Shares of NASDAQ:ERAS traded up $0.99 during trading on Tuesday, hitting $18.83. The company’s stock had a trading volume of 1,613,246 shares, compared to its average volume of 6,388,674. The company has a market capitalization of $5.86 billion, a PE ratio of -20.25 and a beta of 0.66. Erasca has a fifty-two week low of $1.33 and a fifty-two week high of $24.28. The stock’s 50-day moving average price is $16.31 and its two-hundred day moving average price is $14.51.

Institutional Trading of Erasca

Institutional investors and hedge funds have recently modified their holdings of the business. Abel Hall LLC acquired a new position in Erasca in the fourth quarter valued at approximately $58,000. Mariner LLC bought a new stake in shares of Erasca in the 4th quarter worth approximately $40,000. Neuberger Berman Group LLC boosted its position in Erasca by 11.3% during the 4th quarter. Neuberger Berman Group LLC now owns 12,358 shares of the company’s stock valued at $46,000 after purchasing an additional 1,253 shares during the period. Cibc World Markets Corp bought a new position in Erasca during the 4th quarter worth $43,000. Finally, CIBC Bancorp USA Inc. acquired a new stake in Erasca in the third quarter worth $40,000. 67.78% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have issued reports on ERAS. Wall Street Zen lowered Erasca from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Morgan Stanley lifted their price target on shares of Erasca from $12.00 to $21.00 and gave the stock an “equal weight” rating in a research note on Monday, July 20th. Bank of America upped their price target on shares of Erasca from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Tuesday, July 14th. Jefferies Financial Group reiterated a “buy” rating on shares of Erasca in a research note on Tuesday, July 14th. Finally, Mizuho decreased their price objective on shares of Erasca from $28.00 to $26.00 and set an “outperform” rating for the company in a report on Tuesday, May 12th. Eight investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $21.64.

Erasca News Summary

Here are the key news stories impacting Erasca this week:

• Negative Sentiment: Several firms, including Gross Law, Portnoy Law and Robbins Geller, reminded investors that August 10, 2026 is the deadline to seek appointment as lead plaintiff in a class action covering purchases from January 14, 2025, through April 26, 2026. The repeated notices increase the visibility of the legal risk surrounding Erasca. Gross Law Firm notice Portnoy Law Firm announcement
• Negative Sentiment: Hagens Berman said it is investigating allegations that Erasca and senior executives misled investors about the competitive advantage, safety profile and intellectual-property protection of the company’s lead oncology candidate, ERAS-0015. The allegations relate to potential securities-law violations and could create financial, reputational and management distractions if litigation proceeds. Hagens Berman investigation
• Neutral Sentiment: Rosen, Bragar Eagel & Squire, Kahn Swick & Foti, Kaplan Fox, Faruqi & Faruqi, SBS Law and DJS Law issued similar investor notices encouraging shareholders with losses to contact them. These releases are primarily solicitations for potential plaintiffs and do not establish that Erasca is liable or that investors will receive compensation. Rosen Law Firm notice

About Erasca

Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.